On 22 June 2026, CONSUN PHARMA executed an on-market repurchase of 398,000 ordinary shares, according to the company’s Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

The shares were bought at prices ranging between HKD 12.67 and HKD 12.88, translating into a volume-weighted average cost of HKD 12.79 per share and an aggregate consideration of HKD 5.09 million.

After the transaction: • Issued shares (excluding treasury shares) declined by 0.0474% to 839.39 million. • Treasury shares increased to 2.16 million, while total issued shares remained unchanged at 841.55 million because the repurchased shares have not been cancelled.

Repurchase mandate status: • The current mandate, approved on 26 May 2026, authorises the repurchase of up to 84.12 million shares. • Including the latest buyback, 1.82 million shares have been repurchased under this mandate, utilising 2.16% of the authorised limit. • In line with listing rules, CONSUN PHARMA is restricted from issuing new shares or disposing of treasury shares until 22 July 2026.

All repurchases were conducted in compliance with the Main Board Listing Rules, and the company confirmed that all regulatory and corporate approvals were duly obtained.